Tenders/OPEN PROCEDURE FOR THE AWARD TO A CONTRACT RESEARCH ORGANIZATION (CRO) OF SERVICES FOR THE MANAGEMENT OF THE MULTICENTER RANDOMIZED CLINICAL STUDY: “COMBOSEQ - SEQUENCE STRATEGY OF IMMUNEONCOLOGY (IO-IO) VS IO-TYROSINE KINASE INHIBITORS (TKI) FOLLOWED BY TKI IN METASTATIC RENAL CELL CARCINOMA (MRCC): A RANDOMIZED PHASE 3 STUDY MEETURO AND FICOG TRIAL”, VIA THE SINTEL PLATFORM
Open🇮🇹ItalyServices

OPEN PROCEDURE FOR THE AWARD TO A CONTRACT RESEARCH ORGANIZATION (CRO) OF SERVICES FOR THE MANAGEMENT OF THE MULTICENTER RANDOMIZED CLINICAL STUDY: “COMBOSEQ - SEQUENCE STRATEGY OF IMMUNEONCOLOGY (IO-IO) VS IO-TYROSINE KINASE INHIBITORS (TKI) FOLLOWED BY TKI IN METASTATIC RENAL CELL CARCINOMA (MRCC): A RANDOMIZED PHASE 3 STUDY MEETURO AND FICOG TRIAL”, VIA THE SINTEL PLATFORM

Auto-translated from Italian
Original title: PROCEDURA APERTA PER L’AFFIDAMENTO AD UNA CONTRACT RESEARCH ORGANIZATION (CRO) DEI SERVIZI PER LA GESTIONE DELLO STUDIO CLINICO MULTICENTRICO RANDOMIZZATO: “COMBOSEQ - SEQUENCE STRATEGY OF IMMUNEONCOLOGY (IO-IO) VS IO-TYROSINE KINASE INHIBITORS (TKI) FOLLOWED BY TKI IN METASTATIC RENAL CELL CARCINOMA (MRCC): A RANDOMIZED PHASE 3 STUDY MEETURO AND FICOG TRIAL”, MEDIANTE PIATTAFORMA SINTEL
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Published: Nov 4, 2026
Updated: Nov 4, 2026
Source: TED - Tenders Electronic Daily (EU)

About This Opportunity

This is a services contract in the Research sector, with a focus on Scientific Research. Located in Italy, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the Research sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. Interested parties should review the full documentation on the original source before submitting their proposal.

Description

Original language: Italian
PROCEDURA APERTA PER L’AFFIDAMENTO AD UNA CONTRACT RESEARCH ORGANIZATION (CRO) DEI SERVIZI PER LA GESTIONE DELLO STUDIO CLINICO MULTICENTRICO RANDOMIZZATO: “COMBOSEQ - SEQUENCE STRATEGY OF IMMUNEONCOLOGY (IO-IO) VS IO-TYROSINE KINASE INHIBITORS (TKI) FOLLOWED BY TKI IN METASTATIC RENAL CELL CARCINOMA (MRCC): A RANDOMIZED PHASE 3 STUDY MEETURO AND FICOG TRIAL”, MEDIANTE PIATTAFORMA SINTEL PREVISTA CLAUSOLA DI ADESIONE EX-POST A FAVORE DEGLI ENTI DEL CONSORZIO COMPRESA LA FONDAZIONE DEL 300%, COME DA ART. 2 DEL DISCIPLINARE DI GARA

Data provenance

This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on November 4, 2026. Last refreshed today. Original language: Italian. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI has issued 32 procurement notices on BidsFactory, including 1 currently open and 25 awarded contracts. Activity concentrates in General Supplies & Services, Health & Medical, and Research & Innovation. All notices are published for Italy. Notices are distributed via anac_cig, TED - Tenders Electronic Daily (EU), and ANAC (Italy). Most recent publication: November 4, 2026.

Frequently asked questions about this tender

What type of contract is this?

This is a Services contract in the Research & Innovation sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

Where will the contract be performed?

The contract is for delivery in Italy. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.

How can I submit a bid?

Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.

Who is the contracting authority?

This notice was issued by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI in Italy. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

Find tenders like this automatically

Premium shows the full details of every tender like this one and alerts you instantly when a new one is published.

See plans

Key Details

Contract Type
Services
Eligibility
Firms / Consortiums
Language
Italian

Source

ted
TED - Tenders Electronic Daily (EU)
Public Procurement

Contracting Authority

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
🇮🇹Italy

Open expert positions in Italy

Aninver Development Partners is building its team for these assignments. Send your CV in two minutes.

See all consultancy jobs →

Similar Open Tenders in Italy

Open🇮🇹Italy

SUPPLY AND INSTALLATION

🔬 Research & Innovation
Deadline:Premium
Open🇮🇹Italy

Phytosanitary Analyses

🔬 Research & Innovation
Deadline:Premium
Open🇮🇹Italy

GARA EUROPEA A PROCEDURA APERTA EX ART.71 del D.LGS.36/2023 E SS.MM.II. PER L’AFFIDAMENTO DELLA FORNITURA DI UN DIFFRATTOMETRO E ACCESSORI PER LA SEDE RSE DI PIACENZA

🔬 Research & Innovation
Deadline:Premium
Open🇮🇹Italy

982.1 DGR 1032 of 22/06/2026 - att. H - Code 1A2F719 - "LiDAR remote sensing service and survey of the actual state of the networks located in the inhabited area of Casola Valsenio" within the scope of the intervention: "Consolidation works in the inhabited areas declared for consolidation and interventions on landslides in the territory of competence of UT Ravenna", CUP: F71J25000170002.

📐 Architecture & Engineering Services🌍 Environment & Climate
Deadline:Premium
Open🇮🇹Italy

Direct award for CAD Service for histopathological diagnosis obtained through the CE-marked software "Aifora Prostate Cancer Suite", integrated with artificial intelligence, necessary for the research project titled: "Federated learning as a step forward in digital pathology: a multi-centric pipeline and a quality assurance (QA) platform to support diagnosis of prostate cance

🏥 Health & Medical🔬 Research & Innovation
Deadline:Premium
Open🇮🇹Italy

Five-year license to use an existing web software platform, with configuration, startup, testing, training and 24-month warranty, to support the Advanced Cancer Registry - DARE Spoke 2, within the research initiative called "DARE - Digital Lifelong Prevention

💻 Information & Communication Technology🔬 Research & Innovation
Deadline:Premium